Document:

<PAGE>   1
                                                                   Exhibit 10.15

** CERTAIN CONFIDENTIAL MATERIAL CONTAINED IN THIS DOCUMENT HAS BEEN OMITTED AND
FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO 17
C.F.R., SUBSECTION 200.80 (B)(4), 200.83 AND 230.406.**

                                    AGREEMENT

This agreement (the "Agreement") is entered into as of the last date on the
signature page hereof (the "Effective Date") by and among Schering Corporation,
having offices at 2000 Galloping Hill Road, Kenilworth, New Jersey 07033 U.S.A.
and Schering-Plough Ltd., having offices at Toepferstrasse 5, CH6004 Lucerne,
Switzerland (hereinafter collectively referred to as "Schering"), and ICN
Pharmaceuticals, Inc., having offices at ICN Plaza, 3300 Hyland Avenue, Costa
Mesa, California 92626 (hereinafter "ICN") and RibaPharm Inc., having offices at
3300 Hyland Avenue, Costa Mesa, California 92626 (hereinafter "RibaPharm"). (ICN
and RibaPharm are individually and collectively referred to herein as "ICN-RP".)
All references in this Agreement to ICN, RibaPharm and/or ICN-RP shall include
all of their respective Affiliates (as defined below).

                             ARTICLE 1 - DEFINITIONS

The following capitalized terms as used in this Agreement, whether in the
singular or plural, shall have the meanings set forth below:

1.1   "Affiliate" shall mean any individual or entity directly or indirectly
      controlling, controlled by or under common control with, a party to this
      Agreement. For purposes of this Agreement, the direct or indirect
      ownership of fifty percent (50%) or more of the outstanding voting
      securities of an entity, or the right to receive fifty percent (50%) or
      more of the profits or earnings of an entity shall be deemed to constitute
      control. Such other relationship as in fact results in actual control over
      the management, business and affairs of an entity shall also be deemed to
      constitute control. In the case of ICN-RP, Affiliates shall also include,
      without limitation, all subsidiaries, affiliates, joint ventures,
      partnerships, as well as the successors and assigns of any of the
      foregoing, as well as any third party (including but not limited to
      contractors or collaborators) to which ICN-RP is providing ICN-RP Know-How
      and/or funding for use in research and development programs in the Field
      and/or the Option Field.

1.2   "Combination Product" shall mean a single Product which contains two (2)
      or more active ingredients at least one (1) of which is a Compound.

1.3   "Compound" shall mean any and all compounds having potential utility in
      the Field or the Option Field which are discovered or developed by or on
      behalf of ICN-RP or their respective Affiliates (including, without
      limitation, therapeutic proteins, antibodies and small molecules), but
      excluding Ribavirin which is the subject of the 1995 Agreement between ICN
      and Schering-Plough Ltd.

1.4   "Derivative" shall mean, with respect to a compound having potential
      utility in the Field or the Option Field which is discovered or developed
      by or on behalf of ICN-RP or their respective Affiliates, (i) any and all
      structurally related compounds having potential utility in the Field or
      the Option Field which are owned or controlled by ICN-RP or their
      respective Affiliates and which are derived by [REDACTED], and (ii) all
      [REDACTED] of such compound or structurally related compounds.
<PAGE>   2

1.5   "Field" shall mean the treatment or prevention of hepatitis C in humans or
      animals, including, without limitation, through the use of gene therapy,
      gene therapy vaccines, therapeutic proteins or other drug substances;
      provided, however that the compounds Levovirin and Viramidine are excluded
      from the Field.

1.6   "ICN-RP Know-How" shall mean any and all of ICN-RP's or their respective
      Affiliates' information and materials, relating to the research,
      development, registration, manufacture, marketing, use or sale of any
      Compound and/or Product, and which prior to or during the term of this
      Agreement are (i) developed by or on behalf of ICN-RP or their respective
      Affiliates, or (ii) in ICN-RP's or their respective Affiliates' possession
      or control through license or otherwise (provided that ICN-RP is permitted
      to make disclosure thereof to Schering without violating the terms of any
      third party agreement), and which are not generally known.

1.7   "License Patent Rights" shall mean any and all Patent Rights relating to
      Compounds, Derivatives and/or Products which are subject to an exclusive
      license granted to Schering and/or its Affiliates pursuant to Article 2 of
      this Agreement.

1.8   "Net Sales" shall mean with respect to each country in the Territory, the
      amounts actually received by Schering or its Affiliates, or their
      respective sublicensees, from third parties (whether an end-user, a
      distributor or otherwise) for the sale of Compounds and/or Products, and
      exclusive of intercompany transfers or sales among Schering, its
      Affiliates and/or sublicensees in the Territory, less the reasonable and
      customary deductions from such gross amounts including:

      (i)   normal and customary trade, cash and quantity
            discounts, allowances and credits;

      (ii)  credits or allowances actually granted for damaged
            goods, returns or rejections of Product and
            retroactive price reductions;

      (iii) sales or similar taxes (including duties or other governmental
            charges levied on, absorbed or otherwise imposed on the sale of
            Product including, without limitation, value added taxes or other
            governmental charges otherwise measured by the billing amount, when
            included in billing);

                                       2
<PAGE>   3

      (iv)  freight, postage, shipping, customs duties and
            insurance charges, when included in billing;

      (v)   charge back payments and rebates granted to managed health care
            organizations or their agencies, and purchasers and reimbursers or
            to trade customers, including but not limited to, wholesalers and
            chain and pharmacy buying groups;

      (vi)  commissions paid to third parties other than sales
            personnel and sale representatives or sales agents;
            and

      (vii) rebates (or equivalents thereof) granted to or charged by national,
            state or local governmental authorities in a country in the
            Territory.

      In the event that a Product is sold in the form of a Combination Product,
      Net Sales for such Combination Product will be calculated by [REDACTED].

1.9   "Option Field" shall mean the treatment or prevention of viral, fungal or
      bacterial infectious diseases or cancer, or other oncology indications, in
      humans or animals, outside of the Field, including, without limitation,
      through the use of gene therapy, gene therapy vaccines, therapeutic
      proteins or other drug substances. The compounds Levovirin and Viramidine
      are specifically included in the Option Field.

1.10  "Patent Rights" shall mean any and all patent applications and/or patents
      in the Territory which are owned or controlled by ICN-RP and/or their
      respective Affiliates, including any and all substitutions, divisions,
      continuations, continuations-in-part, reissues, renewals, registrations,
      confirmations, re-examinations, extensions, supplementary protection
      certificates or any like filing thereof, and provisional applications of
      any such patents and patent applications and any international equivalent
      of any of the foregoing.

1.11  "Product" shall mean any form or dosage of pharmaceutical composition or
      preparation in final form for sale by prescription, over-the-counter or
      any other method, which is owned or controlled by ICN-RP and/or their
      respective Affiliates and which contains as an active ingredient one or
      more Compounds or Derivatives thereof.

1.12  "Territory" shall mean all of the countries and territories in the world.

                           ARTICLE 2 - GRANT OF RIGHTS

2.1   ICN-RP hereby grants to Schering an exclusive option to obtain an
      exclusive (even as to ICN-RP), worldwide license to use the ICN-RP
      Know-How and under the Patent Rights to make, have made, import, export,
      use, offer for sale and sell Compounds and/or Products in the Field in the
      Territory on and subject to the terms of this Agreement. Any such license
      shall include the right to grant sublicenses and shall include the rights
      to all Derivatives of the licensed Compounds. Schering's exclusive option
      rights under this Section 2.1 shall remain in full force and effect until
      such time as Schering has agreed to acquire exclusive licenses to three
      (3) Compounds/Products in the Field under this Agreement, whereupon such
      option rights shall be exhausted. Effective upon the

                                       3
<PAGE>   4

      exhaustion of Schering's option rights, ICN-RP shall have no further
      obligations under Article 2 or Section 3.1 with respect to Compounds
      and/or Products in the Field. Furthermore, upon the exercise of each such
      option right, ICN-RP's obligations under Sections 3.6 and 3.7 shall be
      transferred to and assumed by Schering in accordance with the terms of
      Sections 3.6 and 3.8.

2.2   The option rights granted to Schering under Section 2.1 with respect to
      any given Compound and/or Product shall be exercisable, in its sole
      discretion, at any time prior to the start of Phase II clinical studies
      for the Compound and/or Product [REDACTED] by providing written notice to
      ICN-RP. ICN-RP shall notify Schering in writing at least [REDACTED] days
      prior to the start of Phase II studies with respect to each Compound
      and/or Product being developed by ICN-RP and/or their respective
      Affiliates in the Field. Promptly after such notice, ICN-RP and/or their
      respective Affiliates (as applicable) shall provide Schering copies of
      and/or direct access to all preclinical and clinical data with respect to
      the Compound and/or Product, and all other information and data in
      ICN-RP's or their respective Affiliates' possession or control relating to
      the Compound and/or Product, including but not limited to all information
      relating to the safety and efficacy of the Compound and/or Product. ICN-RP
      shall cooperate fully with Schering during its due diligence review of
      such data by providing Schering in a timely manner with all information
      necessary to conduct a thorough scientific and commercial evaluation of
      the Compound and/or Product. Following receipt of all information
      reasonably necessary to complete its due diligence review, Schering shall
      have a period of [REDACTED] days in which to notify ICN that it intends to
      exercise its option rights with respect to the Compound and/or Product. In
      the event that ICN-RP fails to provide such information to Schering,
      Schering will notify ICN-RP of any information that has not been provided
      and ICN-RP shall have [REDACTED] days to provide such information;
      provided that Schering's [REDACTED] day due diligence period shall be
      tolled until the later of (i) the expiration of that [REDACTED] day period
      or (ii) the date on which ICN-RP has provided to Schering all such
      information requested by Schering. In the event that Schering does not
      notify ICN-RP that it intends to exercise its option, then Schering's
      option with respect to such Compound and/or Product shall expire upon the
      expiration of the [REDACTED] day period and ICN-RP shall thereafter be
      entitled to develop and commercialize the Compound and/or Product itself
      or to license the Compound and/or Product to a third party.

2.3   Effective upon written notice by Schering to ICN-RP that it is exercising
      its option under Section 2.1 with respect to a given Compound and/or
      Product, ICN-RP shall grant to Schering and/or its designated Affiliate(s)
      an exclusive (even as to ICN-RP), worldwide license to use the ICN-RP
      Know-How and under the Patent Rights to make, have made, import, export,
      use, offer for sale and sell the Compound, Derivatives and/or Products in
      the Territory.

2.4   In the event that any time after exercising its option on any Compound
      and/or Product, Schering decides to grant a sublicense to, or to enter
      into a co-marketing agreement with, a third party (other than a Schering
      Affiliate) in one or more countries in the Territory with respect to the
      Compound and/or Product, ICN-RP shall have the right of first refusal to
      sub-license and/or co-market the Compound and/or Product in such
      country(ies) on

                                       4
<PAGE>   5

      commercially reasonable terms; provided that ICN-RP has in place an
      existing sales force and marketing organization which is determined by
      Schering, in its reasonable discretion, to be of sufficient size, training
      and experience to enable ICN-RP to fulfill the obligations of the proposed
      sublicense or co-marketing agreement in such country(ies). Following such
      notice, ICN-RP shall have a period of [REDACTED] days in which to notify
      Schering of its intent to exercise its right of first refusal. If ICN-RP
      exercises its right of first refusal, the parties shall in good faith
      negotiate and enter into a mutually acceptable license or co-marketing
      agreement, as applicable. If ICN-RP does not exercise its right of first
      refusal within such [REDACTED] day period, then Schering shall be free to
      enter into such an agreement with a third party. If the parties are unable
      to reach agreement on the commercial terms for the license or co-marketing
      agreement within [REDACTED] days of ICN-RP exercising its right of first
      refusal, then Schering shall be free to negotiate and enter into an
      agreement with any third party on substantially similar terms to those
      offered to ICN-RP.

2.5   Nothing in this Agreement, or any license agreements or other agreements
      to be entered into by the parties pursuant to this Agreement, shall be
      construed as conveying to ICN-RP, expressly, by implication, estoppel or
      otherwise, any license or other right or interest in or to any
      information, data, know-how, materials, patent applications, patents or
      other forms of intellectual property owned or controlled by Schering
      and/or its Affiliates.

                              ARTICLE 3 - DILIGENCE

3.1   During the term of this Agreement, ICN-RP shall use commercially
      reasonable efforts, in the exercise of its good faith business judgment,
      to conduct research and development to discover and develop Compounds
      and/or Products in the Field. Such efforts shall be comparable to the
      efforts expended by ICN-RP in the discovery and development of
      pharmaceutical products in other fields in their internal research and
      development programs.

3.2   ICN-RP and their respective Affiliates shall maintain complete and
      accurate records of its research and development activities in the Field
      and the Option Field. ICN-RP shall send to Schering (at the address and to
      the individuals indicated in Section 10.1) reasonably detailed written
      [REDACTED]reports of all research and development activities in the Field
      and the Option Field. Such reports shall be provided to Schering under a
      mutually agreed upon confidentiality agreement (attached hereto as Exhibit
      A). Each such report shall contain sufficient data and information to
      enable Schering to understand in all material respects the nature, scope
      and status of all research projects and other research and development
      activities being performed by ICN-RP and/or their respective Affiliates in
      the Field and the Option Field (including, without limitation, any
      Compounds and/or Products discovered and/or developed by ICN-RP in the
      Field).

3.3   Promptly after the exercise of its option rights with respect to a given
      Compound and/or Product in the Field, Schering shall assume sole
      responsibility, at its expense, for all aspects of the development and
      commercialization of such Compound and/or Product. ICN-RP and their
      respective Affiliates shall transfer to Schering, under mutually agreed
      upon confidentiality provisions, all ICN-RP Know-How related to such
      Compound

                                       5
<PAGE>   6

      and/or Product. Schering shall thereafter use commercially reasonable
      efforts, in the exercise of its good faith business judgment, to develop
      and commercialize the Compound and/or Product, such efforts to be
      comparable to those expended by Schering in the development and
      commercialization of its own products that have similar commercial value,
      status and potential to the Compound and/or Product. All business
      decisions relating to the development and commercialization of the
      Compound and/or Product, including, without limitation, decisions relating
      to the manufacture, sale, design, price, distribution, marketing and
      promotion of the Compound and/or Product, shall be within the sole
      discretion of Schering. Schering shall promptly notify ICN-RP of any
      abandonment of or decision by Schering to abandon or otherwise cease to
      actively pursue such efforts with respect to a Compound and/or Product. In
      any such event, all rights licensed to Schering hereunder with respect to
      such Compound and/or Product shall terminate and revert to ICN-RP;
      provided that nothing herein shall be construed as obligating Schering to
      license, transfer, assign or otherwise convey to ICN-RP any rights, title
      or interest in or to any of Schering's or its Affiliates data,
      information, know-how, trademarks, patents, copyrights or other
      intellectual property or assets in the Field.

3.4   Schering shall be solely responsible, at its expense, for obtaining and
      maintaining regulatory approval to market and sell those Compounds and/or
      Products which are exclusively licensed to Schering pursuant to this
      Agreement. All such regulatory approvals shall be in Schering's or its
      Affiliate's name and Schering shall be solely responsible for all
      communications and meetings with regulatory authorities in the Territory
      with respect thereto. Except as may be specifically requested by Schering,
      in its sole discretion, ICN-RP shall not have any right to participate in
      any such communications and/or meetings with regulatory authorities.

3.5   The obligations of Schering under Sections 3.3 and 3.4 with respect to a
      Compound and/or Product are expressly conditioned upon the continuing
      absence of any significant adverse condition or event which warrants, in
      Schering's reasonable discretion, a delay in the development or
      commercialization of the Compound and/or Product, including, but not
      limited to, an adverse condition or event relating to safety or efficacy,
      or unfavorable pricing, pricing reimbursement, labeling or lack of
      regulatory approval. The obligation of Schering to develop or
      commercialize any such Compound and/or Product shall be delayed or
      suspended so long as (i) in Schering's opinion any such condition or event
      exists, and (ii) such delay or suspension is consistent with the usual
      practice followed by Schering in pursuing the development and
      commercialization of its other pharmaceutical products of similar
      potential value and status.

3.6   ICN-RP shall be primarily responsible, at their expense, for the filing,
      maintenance, prosecution and defense of the Patent Rights in the
      Territory. ICN-RP shall at all times use diligent efforts to fulfill its
      responsibility with respect to the Patent Rights in all countries in the
      Territory. ICN-RP shall consult with Schering with respect to the filing,
      maintenance, prosecution and defense of any and all Patent Rights relating
      to Compounds, Derivatives and/or Products which are subject to the option
      rights, and rights of first and last refusal, granted to Schering or its
      Affiliates under Articles 2 and 5 of this Agreement, and will use its best
      efforts to obtain, maintain and defend such Patent Rights in the
      [REDACTED]. ICN-RP shall give written notice to Schering of any desire

                                       6
<PAGE>   7

      to cease prosecution and/or maintenance of any of the Patent Rights and,
      in such case, shall permit Schering, at Schering's sole discretion, to
      continue prosecution or maintenance at its own expense. If Schering elects
      to continue prosecution or maintenance, ICN-RP, as applicable, shall
      execute such documents and perform such acts, at Schering's expense, as
      may be reasonably necessary to effect an assignment of such Patent Rights
      to Schering. Any such assignment shall be completed in a timely manner to
      allow Schering to continue such prosecution or maintenance. In addition,
      with respect to each Compound and/or Product licensed to Schering pursuant
      to Article 2 and effective as of the date on which Schering exercises its
      option rights in accordance with Section 2.1 with respect thereto,
      Schering shall assume all of ICN-RP's obligations under this Section 3.6
      with regard to any and all Licensed Patent Rights relating to the
      Compounds, Derivatives and/or Products licensed to Schering pursuant to
      Article 2. At such time, ICN-RP shall promptly transfer and assign such
      Licensed Patent Rights to Schering, shall execute and/or cause to be
      executed all documents necessary to perfect Schering's interests therein,
      and thereafter shall, upon request and at Schering's expense, reasonably
      cooperate with Schering to enable Schering to file, prosecute, maintain
      and defend such Licensed Patent Rights.

3.7   In the event that either party becomes aware of any alleged or threatened
      infringement in the Territory of any issued patent within the Patent
      Rights, it will notify the other party in writing to that effect. ICN-RP,
      as applicable, shall be responsible, at its expense, for obtaining a
      discontinuance of such infringement or bringing suit against the third
      party infringer. Schering shall have the right, prior to commencement of
      the trial, suit or action brought by ICN-RP, to join any such suit or
      action, and in such event shall pay one-half of the costs of such suit or
      action. In the event that Schering has joined in the action and shared in
      the costs thereof as set forth above, no settlement, consent judgment or
      other voluntary final disposition of the suit may be entered into without
      the prior consent of Schering. In the event that Schering has not joined
      the suit or action, Schering will reasonably cooperate with ICN-RP in any
      such suit or action and shall have the right to consult with ICN-RP and be
      represented by its own counsel at its own expense; provided that ICN-RP
      shall periodically reimburse Schering for its out-of-pocket costs
      (excluding the costs of retaining its own outside counsel) incurred in
      cooperating with ICN-RP. Any recovery or damages derived from a suit which
      Schering has joined and shared costs shall be used [REDACTED]. Any
      recovery or damages derived from a suit which Schering has not joined
      shall be [REDACTED].

3.8   With respect to each Compound and/or Product licensed to Schering pursuant
      to Article 2 and effective as of the date on which Schering exercises its
      option rights in accordance with Section 2.1 with respect thereto, ICN-RP
      shall transfer to Schering and Schering shall assume all of ICN-RP's
      obligations under Section 3.7 with regard to enforcement of any and all
      Licensed Patent Rights relating to the Compounds, Derivatives and/or
      Products licensed to Schering pursuant to Article 2, including with
      respect to any then ongoing litigation or other actions. ICN-RP shall
      thereafter have no right to initiate, control, defend, settle or otherwise
      participate in any suit or other action relating to the infringement,
      validity, enforceability or defense of any such Licensed Patent Rights, or
      any recovery or damages derived therefrom. ICN-RP shall promptly transfer
      and assign such rights to Schering, shall execute and/or cause to be
      executed all documents

                                       7
<PAGE>   8

      necessary to perfect Schering's interests therein, and thereafter shall,
      upon request and at Schering's expense, reasonably cooperate with Schering
      to enable Schering to enforce and defend such Licensed Patent Rights.

3.9   Any license agreement with respect to Compounds and/or Products in the
      Option Field which is entered into by the parties pursuant to Article 5 of
      this Agreement shall include provisions obligating ICN to transfer to
      Schering, and obligating Schering to assume, all of ICN-RP's obligations
      under Sections 3.6 and 3.7 of this Agreement with regard to filing,
      prosecution, maintenance, defense or enforcement of any and all Patent
      Rights relating to such licensed Compounds and/or Products.

                            ARTICLE 4 - CONSIDERATION

4.1   The parties acknowledge and agree that Schering shall not incur any
      royalties, license fees, milestone payments or reimbursement obligations
      to ICN-RP or their respective Affiliates in connection with the rights
      granted to Schering hereunder or under any exclusive licenses granted
      pursuant to Article 2 except for those expressly set forth herein.
      Schering's sole financial obligation with respect thereto will be the
      payment of the earned royalty on Net Sales of each Compound and/or Product
      exclusively licensed to Schering pursuant to this Article 2 of this
      Agreement and, as applicable, the milestone payments described below. Such
      royalties and milestone payments shall be payable on Schering's and its
      Affiliates' worldwide annual Net Sales of the Compound and/or Product as
      follows:

      As to the [REDACTED] exclusively licensed pursuant to Article 2:

      (i)   [REDACTED] of worldwide annual Net Sales up to [REDACTED]; and

      (ii)  [REDACTED] of worldwide annual Net Sales in excess of [REDACTED], up
            to [REDACTED]; and

      (iii) [REDACTED] of worldwide annual Net Sales in excess of [REDACTED].

      As to the [REDACTED] exclusively licensed pursuant to Article 2:

      (ii)  [REDACTED] of worldwide annual Net Sales up to [REDACTED]; and

      (iii) [REDACTED] of worldwide annual Net Sales in excess of [REDACTED], up
            to [REDACTED]; and

      (iv)  [REDACTED] of worldwide annual Net Sales in excess of [REDACTED].

      As to the exclusively licensed pursuant to Article 2:

      (i)   [REDACTED] of worldwide annual Net Sales up to [REDACTED]; and

                                       8
<PAGE>   9

      (ii)  [REDACTED] of worldwide annual Net Sales in excess of [REDACTED], up
            to [REDACTED]; and

      (iii) [REDACTED] of worldwide annual Net Sales in excess of [REDACTED];
            and

      (iv)  milestone payments (including, if applicable, up-front payments) in
            an amount equal to [REDACTED].

      With respect to each country in the Territory, upon the expiration of the
      last to expire of the Patent Rights in such country incorporating a Valid
      Claim which covers the Compound and/or Product, Schering's royalty
      obligation to ICN-RP under this Section 4.1 with respect to sales of the
      Compound and/or Product in such country shall be reduced by [REDACTED].
      For purposes of this Agreement, the term "Valid Claim" shall mean a
      composition-of-matter or method-of-use claim of an issued and unexpired
      patent included within the Patent Rights, which has not been revoked or
      held unenforceable or invalid by a decision of a court or other
      governmental agency of competent jurisdiction, unappealable or unappealed
      within the time allowed for appeal, and which has not been disclaimed,
      denied or admitted to be invalid or unenforceable through reissue,
      disclaimer or estoppel.

      In addition, all of Schering's royalty obligations under this Article 4
      shall expire with respect to a given Compound and/or Product in any
      country in the Territory at such time as a product containing the same
      active ingredient as the Compound and/or Product being marketed by
      Schering hereunder is being sold by any third party in such country.

4.2   Royalties shall be paid quarterly within [REDACTED] days after the close
      of each calendar quarter. Concurrently with such payments, Schering shall
      provide ICN-RP, as applicable, with a written report for the calendar
      quarter showing the Net Sales of Product(s) and/or Compound(s) sold by
      Schering, its Affiliates and its sublicensees in the Territory during such
      calendar quarter and the royalties payable for such calendar quarter All
      royalty payments shall be paid in U.S. dollars (to the extent that free
      conversions to United States dollars is permitted) by bank wire transfer
      in immediately available funds to an account designated by ICN-RP.
      Royalties shall be deemed payable by the entity making the Net Sales from
      the country in which earned in local currency and subject to foreign
      exchange regulations then prevailing. The rate of exchange to be used in
      any such conversion from the currency in the country where such Net Sales
      are made shall be the rate of exchange used by Schering Corporation for
      reporting such sales for United States financial statement purposes. If,
      due to restrictions or prohibitions imposed by national or international
      authority, payments cannot be made as aforesaid, the parties shall consult
      with a view to finding a prompt and acceptable solution, and Schering will
      deal with such monies as ICN-RP may lawfully direct at no additional
      out-of-pocket expense to Schering. Notwithstanding the foregoing, if
      royalties in any country cannot be remitted to ICN-RP for any reason
      within [REDACTED] months after the end of the calendar quarter during
      which they are earned, then Schering shall be obligated to deposit the
      royalties in a bank account in such country in the name of ICN-RP, as
      applicable.

                                       9
<PAGE>   10

4.3   Schering and its Affiliates shall keep complete and accurate records in
      sufficient detail to enable the royalties payable hereunder to be
      determined. Upon [REDACTED] days prior written notice from ICN-RP,
      Schering shall permit an independent certified public accounting firm of
      nationally recognized standing selected by ICN-RP, at ICN-RP's expense, to
      have access during normal business hours to examine pertinent books and
      records of Schering and/or its Affiliates as may be reasonably necessary
      to verify the accuracy of the royalty reports hereunder. The examination
      shall be limited to pertinent books and records for any year ending not
      more than [REDACTED] months prior to the date of such request. An
      examination under this Section 4.3 shall not occur more than [REDACTED] in
      any calendar year. Schering may designate competitively sensitive
      information, which such auditor may not disclose to ICN-RP; provided,
      however, that such designation shall not encompass the auditor's
      conclusions. The accounting firm shall disclose to ICN-RP only whether the
      royalty reports are correct or incorrect and the specific details
      concerning any discrepancies. No other information shall be provided to
      ICN-RP. All such accounting firms shall sign a confidentiality agreement
      (in form and substance reasonably acceptable to Schering) as to any of
      Schering's or its Affiliates' confidential information which they are
      provided, or to which they have access, while conducting any audit
      pursuant to this Section 4.3.

4.4   Schering shall include in each sublicense granted by it pursuant to this
      Agreement a provision requiring the sublicensee to make reports to
      Schering, to keep and maintain records of sales made pursuant to such
      sublicense and to grant access to such records by ICN-RP's independent
      accountant to the same extent required of Schering under this Agreement.

4.5   Upon the expiration of [REDACTED] months following the end of any calendar
      year, the calculation of royalties payable under this Agreement with
      respect to such year shall be binding and conclusive upon the parties, and
      Schering, its Affiliates and its sublicensees shall be released from any
      liability or accountability with respect to royalties for such calendar
      year; provided that expiration of such [REDACTED] month period shall not
      affect any claim which is already in dispute between the parties with
      respect to royalties during such calendar year.

4.6   If at any time, any jurisdiction within the Territory requires the
      withholding of income taxes or other taxes imposed upon payments set forth
      in this Article 4, Schering shall make such withholding payments as
      required and subtract such withholding payments from the payments set
      forth in this Article 4, or if applicable, ICN-RP will promptly reimburse
      Schering or its designee(s) of the amount of such payments. Schering shall
      provide ICN-RP, as applicable, with documentation of such withholding and
      payment in a manner that is satisfactory for purposes of the U.S. Internal
      Revenue Service. Any withholdings paid when due hereunder shall be for the
      account of ICN-RP, as applicable, and shall not be included in the
      calculation of Net Sales. Payments of withholding taxes made by Schering
      pursuant to this Section 4.6 will be made based upon financial information
      to be provided to Schering by ICN-RP and, to the extent that such
      information is incorrect or incomplete, ICN-RP shall be liable for any
      fine, assessment or penalty, or any deficiency, imposed by any taxing
      authority in the Territory for any deficiency in the amount of any such
      withholding or the failure to make such withholding

                                       10
<PAGE>   11

      payment. If Schering is required to pay any such deficiency, or any such
      fine, assessment or penalty for any such deficiency, ICN-RP shall promptly
      reimburse Schering for such payments, which shall not be included in the
      calculation of Net Sales.

                   ARTICLE 5 - RIGHT OF FIRST AND LAST REFUSAL

5.1   In addition to the rights granted to Schering in Article 2, ICN-RP hereby
      grants to Schering the right of first refusal to obtain an exclusive (even
      as to ICN-RP), worldwide license and/or other worldwide rights to use the
      ICN-RP Know-How and under the Patent Rights to Compounds and/or Products
      in the Option Field in the Territory as and to the extent provided in this
      Article 5. If at any time during the term of this Agreement (i) Schering
      wishes to license from ICN-RP a Compound/Product in the Option Field as
      described in the semi-annual report referred to as Section 3.2 herein; or
      (ii) ICN-RP intends to offer a license of any kind or to assign, transfer
      or otherwise convey any other rights (e.g., distributorship, co-marketing,
      co-promotion, etc.) to a Compound and/or Product in the Option Field in
      any or all countries in the Territory worldwide, each party shall notify
      the other in writing to that effect. Where ICN-RP notifies Schering of its
      intent to offer a license or other rights to a Compound/Product, ICN-RP
      shall provide Schering a detailed summary of all information with regard
      to preclinical and clinical development of the Compound and/or Product,
      including but not limited to all information relating to the safety and
      efficacy of the Compound and/or Product. Similarly, where Schering
      notifies ICN-RP in writing of its intent to exclusively license worldwide
      or obtain other worldwide rights to use the ICN-RP Know-How and under
      Patent Rights to Compounds/Products in the Option Field, ICN-RP shall
      provide Schering a detailed summary of all information with regard to
      preclinical and clinical development of the Compound and/or Product,
      including but not limited to all information relating to the safety and
      efficacy of the Compound and/or Product. In either instance, Schering
      shall have a period of the [REDACTED] days (the "Evaluation Period") in
      which to evaluate such information and to notify ICN-RP of its intent to
      exercise its right of first refusal by providing written notice to that
      effect. During the Evaluation Period, ICN-RP shall upon request and at
      Schering's expense, provide Schering with reasonable access, in a timely
      manner (i.e., within [REDACTED] days of such written notice) to all other
      information and data in its or its Affiliates' possession or control
      relating to the Compound and/or Product to enable Schering to complete a
      due diligence review of the Compound and/or Product. In the event that
      ICN-RP fails to provide such information to Schering, Schering will notify
      ICN-RP of the information that has not been provided and ICN-RP shall have
      [REDACTED] days to provide such information; provided that the Evaluation
      Period shall be tolled until the later of (i) the expiration of that
      [REDACTED] day period or (ii) the date on which ICN-RP has provided to
      Schering all such information requested by Schering. Nothing contained
      herein shall be construed as providing any right of first refusal or right
      of last refusal to Schering with respect to any Compound and/or Product
      that ICN-RP, in its sole discretion, decides to develop and commercialize
      the Compound and/or Product itself, utilizing its own personnel and
      resources.

5.2   In the event that Schering exercises its right of first refusal with
      respect to a given Compound and/or Product, then the parties shall in good
      faith exclusively negotiate the

                                       11
<PAGE>   12

      terms of a mutually acceptable exclusive (even as to ICN-RP), worldwide
      license or other form of agreement on commercial terms to be agreed upon
      by the parties. If the parties are unable to reach agreement on the
      commercial terms for the agreement within [REDACTED] days of Schering's
      exercising its right of first refusal, then ICN-RP shall be free to enter
      into negotiations with respect to such Compound and/or Product with a bona
      fide pharmaceutical and/or biotechnology company (not affiliated with
      ICN-RP or their respective officers, directors or employees) having
      sufficient resources to develop and commercialize the Compound and/or
      Product. ICN-RP shall not disclose to such pharmaceutical/biotechnology
      company any information relating to the Compound and/or Product which has
      not been previously disclosed to Schering. In the event that ICN-RP and
      the pharmaceutical/biotechnology company agree upon the commercial terms
      for licensing the Compound and/or Product, then ICN-RP shall disclose to
      Schering the full and complete agreement between itself and the
      pharmaceutical/biotechnology company, and offer substantially similar
      commercial terms to Schering. The commercial terms presented to Schering
      shall reflect in all respects a genuine offer made by such
      pharmaceutical/biotechnology company in good faith with the intent of
      developing such Compound and/or Product for commercialization. Schering
      shall have [REDACTED] days in which to accept or reject such terms. If
      Schering does not accept the terms offered by ICN-RP within such
      [REDACTED] day period, then ICN-RP shall be free enter into an agreement
      with the pharmaceutical/biotechnology company on substantially similar
      terms that were offered to Schering. ICN-RP shall not offer to license the
      Compound and/or the Product to any such pharmaceutical/biotechnology
      company on commercial terms which are in the aggregate more favorable to
      the pharmaceutical/biotechnology company than those last offered to
      Schering without first offering Schering the rights on such terms.

                        ARTICLE 6 - TERM AND TERMINATION

6.1   This Agreement shall begin on the Effective Date and remain in full force
      and effect, unless earlier terminated in accordance with Section 6.2,
      until the later of (i) twelve (12) years from the Effective Date, or (ii)
      the expiration of the Exclusive License and Supply Agreement between ICN
      and Schering-Plough Ltd., dated July 28, 1995, as amended.

6.2   This Agreement may be terminated, in whole or in part, by Schering or by
      ICN-RP upon written notice to the other parties in the event of a material
      breach of this Agreement by the other party that is continuing [REDACTED]
      days after the non-breaching party gives the breaching party notice of
      such breach specifying in reasonable detail the particulars of the alleged
      breach; provided, however, that if the breach is limited to a specific
      Compound and/or Product, then such termination right shall only apply with
      respect to that Compound and/or Product.

6.3   In the event of termination by ICN-RP under Section 6.2 with respect to a
      given Compound and/or Product due to a failure by Schering to fulfill its
      diligence obligations under Sections 3.3, 3.4 and 3.5 in one or more
      countries in the Territory, all licenses granted to Schering with respect
      to such Compound and/or Product in such country(ies) shall terminate and
      revert to ICN-RP; provided that nothing herein shall be construed as
      obligating Schering to license, transfer, assign or otherwise convey to
      ICN-RP any rights,

                                       12
<PAGE>   13

      title or interest in or to any of Schering's or its Affiliates data,
      information, know-how, trademarks, patents, copyrights or other
      intellectual property or assets in the Field.

6.4   All exclusive licenses to Compounds and/or Products which are granted to
      Schering pursuant to Section 2.3 of this Agreement shall survive the
      expiration of this Agreement under Section 6.1 and, unless earlier
      terminated pursuant to Sections 6.2 and 6.3, shall continue in full-force
      and effect on a product-by-product and country-by-country basis on the
      terms and conditions set forth herein until such time as Schering's
      royalty obligations with respect to such Compound and/or Product expires
      in the country. Upon expiration of each such license in a given country,
      the license shall become a paid-up, irrevocable, royalty-free
      non-exclusive license in the country.

                             ARTICLE 7 - INSOLVENCY

7.1   All rights and licenses granted under or pursuant to this Agreement by
      ICN-RP to Schering are, for all purposes of Section 365(n) of Title 11 of
      the United States Code ("Title 11"), licenses of rights to "intellectual
      property" as defined in Title 11. ICN-RP agree during the term of this
      Agreement to create and maintain current copies or, if not amenable to
      copying, detailed descriptions or other appropriate embodiments, to the
      extent feasible, of all such intellectual property. If a case is commenced
      by or against ICN-RP under Title 11, then ICN-RP (in any capacity,
      including debtor-in-possession) and its successors and assigns (including,
      without limitation, a Title 11 Trustee) shall,

      (1)   as Schering may elect in a written request,
            immediately upon such request:

            (i)   perform all of the obligations provided in this Agreement to
                  be performed by ICN-RP including, where applicable and without
                  limitation, providing to Schering portions of such
                  intellectual property (including embodiments thereof) held by
                  ICN-RP and such successors and assigns or otherwise available
                  to them; or

            (ii)  provide to Schering all such intellectual property (including
                  all embodiments thereof) held by ICN-RP and such successors
                  and assigns or otherwise available to them; and

      (2)   not interfere with the rights of Schering under this Agreement, or
            any agreement supplemental hereto, to such intellectual property
            (including such embodiments), including any right to obtain such
            intellectual property (or such embodiments) from another entity.

      If a Title 11 case is commenced by or against ICN-RP, and this Agreement
      is rejected as provided in Title 11, and Schering elects to retain its
      rights hereunder as provided in Title 11, then ICN-RP (in any capacity,
      including debtor-in-possession) and its successors and assigns (including,
      without limitation, a Title 11 Trustee) shall provide to Schering all such
      intellectual property (including all embodiments thereof) held by ICN-RP
      and such successors and assigns, or otherwise available to them,
      immediately upon Schering's written request. Whenever ICN-RP, or any of
      their successors or assigns provides to Schering any of the intellectual
      property licensed hereunder (or any embodiment thereof)

                                       13
<PAGE>   14

      pursuant to this Section 11.8, Schering shall have the right to perform
      the obligations of ICN-RP hereunder with respect to such intellectual
      property, but neither such provision nor such performance by Schering
      shall release ICN-RP from any such obligation or liability for failing to
      perform it.

      All rights, powers and remedies of Schering provided herein are in
      addition to and not in substitution for any and all other rights, powers
      and remedies now or hereafter existing at law or in equity (including,
      without limitation, Title 11) in the event of the commencement of a Title
      11 case by or against ICN-RP. Schering, in addition to the rights, power
      and remedies expressly provided herein, shall be entitled to exercise all
      other such rights and powers and resort to all other such remedies as may
      now or hereafter exist at law or in equity (including, without limitation,
      Title 11) in such event. The parties agree that they intend the foregoing
      Schering rights to extend to the maximum extent permitted by law,
      including, without limitation, for purposes of Title 11:

      (1)   the right of access to any intellectual property (including all
            embodiments thereof) of ICN-RP, or any third party with whom ICN-RP
            contracts to perform an obligation of ICN-RP under this Agreement,
            and, in the case of the third party, which is necessary for the
            development, registration, manufacture and marketing of Licensed
            Compounds and/or Licensed Products; and

      (2)   the right to contract directly with any third party described in (i)
            to complete the contracted work.

      In the event of any insolvency of ICN-RP and if any statute and/or
      regulation in any country in the Territory requires that there be a
      specific grant or specific clause(s) in order for Schering to obtain the
      rights and benefits as licenses under this Agreement which are analogous
      to those rights under Section 365(n) of Title 11 of the United States
      Code, then this Agreement shall be deemed to include any and all such
      required grant(s), clause(s) and/or requirements.

                              ARTICLE 8 - WARRANTY

8.1   Each of Schering and ICN-RP hereby represents and warrants to the other
      parties that as of the Effective Date:

      (a)   it is a corporation or entity duly organized and validly existing
            under the laws of the state or other jurisdiction of its
            incorporation or formation;

      (b)   the execution, delivery and performance of this Agreement by such
            party has been duly authorized by all requisite corporate action;

      (c)   it has the power and authority to execute and deliver this Agreement
            and to perform its obligations hereunder;

                                       14
<PAGE>   15

      (d)   the execution, delivery and performance by such party of this
            Agreement and its compliance with the terms and provisions hereof
            does not and will not conflict with or result in a breach of any of
            the terms and provisions of or constitute a default under (i) a loan
            agreement, guaranty, financing agreement, agreement affecting a
            product or other agreement or instrument binding or affecting it or
            its property; (ii) the provisions of its charter or operative
            documents or bylaws; or (iii) any order, writ, injunction or decree
            of any court or governmental authority entered against it or by
            which any of its property is bound;

      (e)   this Agreement has been duly authorized, executed and delivered and
            constitutes such party's legal, valid and binding obligation
            enforceable against it in accordance with its terms subject, as to
            enforcement, to bankruptcy, insolvency, reorganization and other
            laws of general applicability relating to or affecting creditors'
            rights and to the availability of particular remedies under general
            equity principles; and

      (f)   it shall comply with all applicable material laws and regulations
            relating to its activities under this Agreement.

8.2   ICN-RP hereby represents, warrants and covenants to Schering that:

      (a)   as of the Effective Date, ICN-RP has not within the [REDACTED] month
            period immediately preceding the Effective Date of this Agreement,
            assigned, transferred conveyed or otherwise encumbered or disposed
            of (other than to an Affiliate as defined herein) any of the
            know-how, patent applications, patents and other intellectual
            property and assets arising in connection with research and
            development in the Field and the Option Field which has been
            conducted by or on behalf of ICN-RP (the "Existing Intellectual
            Property");

      (b)   as of the Effective Date it has the full right, power and authority
            to grant all of the right, title and interest in the option rights
            granted under Articles 2 and 5 hereof;

      (c)   during the term of this Agreement and except as expressly permitted
            under Sections 2.2 and 5.2, ICN-RP shall not take any action which
            would (i) assign, transfer or otherwise convey to any third party
            any right, title or other interest in or to the Existing
            Intellectual Property; (ii) create any liens, charges or
            encumbrances with respect to the Existing Intellectual Property or
            (iii) give rise to any third party claim of ownership with respect
            to the Existing Intellectual Property, whatsoever; and

      (d)   during the term of this Agreement, ICN-RP shall not commit any
            actions or omissions which would diminish or otherwise be
            inconsistent with the option rights granted to Schering hereunder.

8.3   With respect to each exclusive license obtained by Schering under Article
      2 of this Agreement, ICN-RP shall represent, warrant and covenant that, as
      of the date such license becomes effective pursuant to Section 2.3:

                                       15
<PAGE>   16

      (a)   to the best of ICN-RP's knowledge, the relevant Licensed Patent
            Rights are subsisting and are not invalid or unenforceable, in whole
            or in part;

      (b)   it has the full right, power and authority to grant all of the
            right, title and interest in the licenses granted under Article 2
            hereof;

      (c)   it has not assigned, transferred, conveyed or otherwise encumbered,
            and during the term of this Agreement will not assign, transfer,
            convey of otherwise encumber, its right, title and interest in the
            relevant Licensed Patent Rights or ICN-RP Know-How (except in
            accordance with this Agreement);

      (d)   to the best of ICN-RP's knowledge, it is the sole and exclusive
            owner of the relevant Licensed Patent Rights and ICN-RP Know-How,
            all of which is free and clear of any liens, charges and
            encumbrances, and no other person, corporate or other private
            entity, or governmental entity or subdivision thereof, has or shall
            have any claim of ownership with respect to such Licensed Patent
            Rights and ICN-RP Know-How, whatsoever;

      (e)   during the term of this Agreement, ICN-RP shall not take any action
            which would (i) create any liens, charges or encumbrances with
            respect to the relevant Licensed Patent Rights and ICN-RP Know-How
            whatsoever, or (ii) give rise to any third party claim of ownership
            with respect to such Licensed Patent Rights and ICN Know How,
            whatsoever;

      (f)   to the best of ICN-RP's knowledge, the relevant Licensed Patent
            Rights and ICN-RP Know-How, and the development, manufacture, use,
            distribution, marketing, promotion and sale of the Compound and/or
            Product do not interfere or infringe on any intellectual property
            rights owned or possessed by any third party;

      (g)   to the best of ICN-RP's knowledge, there are no third party pending
            patent applications which, if issued, may cover the development,
            manufacture, use, distribution, marketing, promotion or sale of the
            Compound and/or Product; and

      (h)   it has disclosed to Schering all ICN-RP Know-How and other relevant
            information required to be disclosed hereunder, including, without
            limitation, information relating to the relevant Licensed Patent
            Rights, and the Compound and/or Product.

8.4   Any license agreement entered into by the parties pursuant to Article 5
      shall contain essentially the same representations, warranties and
      covenants with respect to the Compounds and/or Products licensed
      thereunder as are set forth in this Article 8.

                           ARTICLE 9 - INDEMNIFICATION

9.1   ICN-RP shall indemnify, defend and hold harmless Schering, its Affiliates,
      and their respective directors, officers, employees and agents, and the
      successors and assigns of any

                                       16
<PAGE>   17

      of the foregoing from and against any and all liability, damages, losses,
      claims, actions, judgments and costs (including, without limitation,
      reasonable legal fees) arising from or related to: (i) any negligent act
      or omission or willful misconduct of ICN-RP (or their respective
      Affiliates) in connection with any Compound and/or Product (including,
      without limitation, product liability claims); and/or (ii) a material
      breach of any of the representations or warranties ICN-RP hereunder.
      Notwithstanding the foregoing, ICN-RP shall have no indemnification
      obligations under this Agreement with respect to claims, demands, costs or
      judgments to the extent caused by the gross negligence or willful
      misconduct of Schering.

9.2   Schering shall indemnify, defend and hold harmless ICN-RP, their
      respective Affiliates, and their respective directors, officers, employees
      and agents, and the successors and assigns of any of the foregoing from
      and against any and all liability, damages, losses, claims, actions,
      judgments and costs (including without limitation, reasonable legal fees)
      arising from or related to: (i) any negligent act or omission or willful
      misconduct of Schering (or its Affiliates) in the development,
      manufacture, distribution, sale, use or other exploitation of any Compound
      and/or Product (including, without limitation, product liability claims);
      and/or (ii) a material breach of any of the representations or warranties
      of Schering hereunder.

9.3   Each party acknowledges and agrees that during the term of this Agreement
      it shall maintain adequate insurance or self-insurance program for
      liability purposes, including products liability and contractual liability
      insurance, to cover such party's obligations under this Agreement. Each
      party shall provide the other party with evidence of such insurance and/or
      self-insurance program, upon request.

                      ARTICLE 10 - MODIFICATION AND WAIVER

10.1  No cancellation, modification, amendment, deletion, addition or other
      change in this Agreement or any provision herein, or waiver of any right
      or remedy herein provided, shall be effective for any purpose unless
      specifically set forth in writing and signed by the party to be bound
      thereby. No waiver of any right or remedy in respect of any occurrence or
      event shall be deemed a waiver of such right or remedy in respect of such
      occurrence or event on any other occasion.

                               ARTICLE 11 - NOTICE

11.1  Any notice required or permitted hereunder shall be communicated in
      writing and shall be sent by registered mail, prepaid courier or facsimile
      transmission to the addresses set out below or to such other address as
      may be specified, in writing, by the party who changes its address.

      To ICN:           ICN Pharmaceutical Inc.
                        ICN Plaza
                        3300 Hyland Avenue
                        Costa Mesa, California  92626
                        Attention: President

                                       17
<PAGE>   18

                        Facsimile:  714-641-7276

      To RibaPharm:     RibaPharm Inc.
                        3300 Hyland Avenue
                        Costa Mesa, California  92626
                        Attention: President
                        Facsimile:

      To Schering:      Schering Corporation
                        2000 Galloping Hill Road
                        Kenilworth, New Jersey 07033
                        Attention: Vice President, Business
                        Development
                        Facsimile: 908-298-7366

                  with copies to:

                        Attention: Legal Dept. - Staff Vice President, Licensing
                        Facsimile: 908-298-2739

      All written communications shall be deemed to be received by the
      addressees as follows: (i) by registered mail: five (5) business days
      after dispatch by notifying party; (ii) by prepaid courier: two (2)
      business days after dispatch by notifying party; or (iii) by facsimile
      transmission: one (1) business day after dispatch by notifying party. A
      copy of any notice sent by facsimile transmission shall thereafter be
      dispatched by registered mail.

                             ARTICLE 12 - PUBLICITY

12.1  Neither party shall use the name of the other party nor the name of the
      other party's Affiliates for any promotional purposes without the prior
      written consent of the party whose name is proposed to be used. No news
      release, publicity or other public announcement, either written or oral,
      regarding the terms or existence of this Agreement or performance
      hereunder, shall be made by either party without the prior written
      agreement of the other party. Each of the parties further agrees not to
      disclose to any third party the existence or terms of this Agreement
      without the prior written consent of the other party hereto. Nothing in
      the foregoing, however, shall prohibit a party from making such
      disclosures to the extent required under applicable federal or state
      securities laws or any rule or regulation of any nationally recognized
      securities exchange; provided that in such event the disclosing party
      shall notify and consult with the other party prior to such disclosure
      and, where applicable, shall diligently seek confidential treatment to the
      extent available.

                         ARTICLE 13 - GENERAL PROVISIONS

13.1  The relationship between ICN-RP and Schering established by this Agreement
      is that of independent contractors. Nothing in this Agreement shall be
      construed to create any other relationship between ICN-RP and Schering,
      and neither party shall have any right,

                                       18
<PAGE>   19

      power or authority to assume, create or incur any expense, liability or
      obligation, express or implied, on behalf of the other.

13.2  This Agreement shall be governed by and construed according to the laws of
      New Jersey, without regard to conflicts of laws principles. In the event
      of any dispute between the parties arising from or relating to this
      Agreement, the parties agree to submit themselves, for the purpose of
      resolving such dispute, to the exclusive jurisdiction of either the
      Federal or State courts of New Jersey.

13.3  This Agreement shall be deemed to be jointly prepared by the Parties, and
      any ambiguity herein shall not be construed for or against either party.

13.4  No account of the headings to the paragraphs of this Agreement shall be
      taken when interpreting the meaning of this Agreement.

13.5  This Agreement may be executed in multiple counterparts, each of which
      shall be deemed to be an original, and all such counterparts shall
      constitute but one instrument.

13.6  This Agreement and each and every one of its provisions shall be binding
      upon the executors, administrators, successors and permitted assigns of
      the Parties hereto. Without limiting the foregoing, and for the avoidance
      of doubt, ICN may, without the consent of Schering or any Affiliate of
      Schering, assign to RibaPharm any of ICN's rights to receive payments
      under this Agreement.

13.7  All terms and conditions of this Agreement are severable, and the
      invalidity, illegality or unenforceability of any term or condition shall
      not affect the validity, legality or enforceability of the remaining terms
      and conditions.

13.8  This Agreement constitutes the entire agreement between the Parties hereto
      respecting the subject matter herein and supersedes all prior or
      contemporaneous negotiations, agreements and understandings, whether
      written or oral. Neither party has relied upon any statements, promises,
      representations or claims of the other party, other than those expressly
      set forth in this Agreement, in agreeing to enter into and be bound by the
      terms of this Agreement.

                                       19
<PAGE>   20

IN WITNESS WHEREOF, the parties have caused their duly authorized
representatives to execute this Agreement.

SCHERING  CORPORATION

By:
      ------------------------------
      (authorized representative)

Name:   David Poorvin, Ph.D.
      ------------------------------
Title:     Vice President
      ------------------------------

ICN PHARMACEUTICALS, INC.

By:
     ---------------------------------
    (authorized representative)

Name:
     ---------------------------------
Title:
     ---------------------------------

SCHERING-PLOUGH LTD.

By:
      ------------------------------
      (authorized representative)

Name:   David Poorvin, Ph.D.
      ------------------------------
Title:     Prokurist
      ------------------------------

 RIBAPHARM INC.

 By:
      ---------------------------------
     (authorized representative)

 Name:
      ---------------------------------
 Title:
      ---------------------------------

                                       20
<PAGE>   21

                                    EXHIBIT A

                                SECRECY AGREEMENT

EFFECTIVE DATE:   The last date on the signature page hereof ("Effective Date")

BY AND BETWEEN:   SCHERING CORPORATION, 2000 Galloping Hill Road, Kenilworth,
                  New Jersey 07033 ("SCHERING")
AND

DISCLOSING PARTY'S
NAME:

DISCLOSING PARTY'S
ADDRESS:                                                            ("COMPANY")

DISCLOSURE:       Certain written technical data, materials, and/or information
                  provided by COMPANY to SCHERING which is (i) disclosed
                  pursuant to this Agreement and (ii) clearly identified in
                  writing as "Confidential" when disclosed; and which relates to
                                    (the "Disclosure"). In the event the
                  Disclosure is in a manner other than in writing, it shall be
                  reduced to written form, marked "Confidential" and transmitted
                  to SCHERING within ten (10) business days of the Disclosure to
                  SCHERING.

      In consideration for said Disclosure and the economic importance thereof
to COMPANY, such Disclosure shall be made on the following basis:

      1. SCHERING agrees, for a period of five (5) years following the Effective
Date, to retain the Disclosure made to it by or on behalf of Company, in
confidence. SCHERING further agrees that it will not, without the written
consent of COMPANY, use the Disclosure for any purpose other than that indicated
herein. These restrictions shall not apply to information which:

      (i)   is or becomes public knowledge (through no fault of SCHERING), or

      (ii)  is made lawfully available to SCHERING by an independent third
            party, or

      (iii) is already in SCHERING's possession at the time of receipt from
            COMPANY, or

      (iv)  is independently developed by employees of SCHERING or its parent
            corporation or their respective affiliates and/or subsidiaries (and
            such independent development can be properly demonstrated without
            the aid or use of the Disclosure), or

      (v)   is required by law, regulation, rule, act, or order of any
            governmental authority or agency to be disclosed.

<PAGE>   22

      2. SCHERING shall only provide the Disclosure to those of its, its parent
corporation's, and their respective affiliates' and subsidiaries' officers and
employees who are directly concerned with the Disclosure.

      3. COMPANY shall neither disclose to SCHERING nor induce SCHERING to use
any secret or confidential information or material belonging to others,
including former employers, if any.

      4. SCHERING agrees to promptly return the Disclosure upon request;
provided, however, that SCHERING's legal counsel may retain one copy of the
Disclosure in a secure location for purposes of identifying SCHERING's
obligations under this Agreement.

      5. This Agreement shall be construed in accordance with New Jersey law
without regard to the conflict of laws rules or principles thereof. It is
understood and agreed that both parties submit to the jurisdiction of New Jersey
state and federal courts.

      6.  This Agreement may only be amended by a written
instrument signed by both parties hereto.

      IN WITNESS WHEREOF, the parties have caused this Agreement to be executed,
by duly authorized representatives, as of the last date written below.

[Company Name]

By:
      ----------------------------

Name:
      ----------------------------

Title:
      ----------------------------

Date:
      ----------------------------

SCHERING CORPORATION

By:
      ----------------------------

Name:
      ----------------------------

Title:
      ----------------------------

Date:
      ----------------------------

                                       2<PAGE>   1
                                                                    EXHIBIT 10.1
[Nasdaq Logo]

Steven J. Randich
Executive Vice President
Chief Technology Officer

                                                April  27, 2001
Mr. Robert Warshaw
Chief Executive Officer
OptiMark Holdings, Inc.
10 Exchange Place, 24th Floor
Jersey City, NJ  07302

Dear Bob:

As you are well aware, The Nasdaq Stock Market, Inc. ("Nasdaq") has determined
that a dual development track for SuperMontage (i.e. "Plan B") is no longer
consistent with our business needs. Based on conversations between Nasdaq and
OptiMark Holdings, Inc. ("OptiMark") that have occurred over the past month or
so, led by Dan Moore and Hector Olmeda, respectively, we have collectively
identified a workable alternative. This alternative provides for staff
augmentation of Nasdaq's Multiple Parallel Architecture ("MPA") design,
development and implementation teams with qualified OptiMark resources. We
believe that through staff augmentation, knowledge transfer, and other technical
assistance from OptiMark, the success of our MPA development effort will be
enhanced.

On October 2, 2000, Nasdaq and OptiMark entered into a Services and License
Agreement (the "Agreement") that provided, in part, for Nasdaq to utilize
OptiMark's development resources as an alternative development track for
Nasdaq's SuperMontage system. Given the newly agreed upon work approach, we
hereby request your agreement with respect to the following amendment to the
Agreement, effective as of the date first set forth above, that will allow
Nasdaq to continue utilizing OptiMark's development resources on new projects:

         1.   Phases and Stages of the SuperMontage Effort. Attachment 8 and
              Section 4 of the Agreement are deleted in their entirety and
              replaced with the scope of services set forth in the attached Task
              Order ("New Services"). The second sentence of Section 5.4 and the
              last line of Section 28.1 (the reference to Attachment 8) are also
              deleted. The Task Order may not be modified except with the prior
              written consent of Nasdaq and OptiMark.

         2.   Nasdaq Payments. Section 7 of the Agreement is deleted in its
              entirety and replaced with the following:

         (a)      Within five (5) days prior to the beginning of each month,
                  OptiMark shall provide Nasdaq with a work plan (the "Monthly
                  Work Plan") that sets forth the services to be performed in
                  the upcoming month. The parties agree that the value of such
                  services (such value to be determined on a time and materials
                  basis pursuant to the rates listed in Attachment 2) should
                  equal approximately $700,000 per month. Further, each Monthly
                  Work Plan shall include the following information with respect
                  to each OptiMark employee or subcontractor who is expected to
                  perform work in support of any of the New Services to be
                  provided to Nasdaq during the month: (i) name; (ii) title;
                  (iii) rate (as listed in
<PAGE>   2
                  Attachment 2); (iii) number of hours expected to be worked
                  during the month; and (iv) the New Services expected to be
                  performed during the month. Nasdaq shall have four (4) days
                  following its receipt of the Monthly Work Plan to notify
                  OptiMark of any modifications it has to the Monthly Work Plan
                  and the Monthly Work Plan shall be modified accordingly,
                  subject to OptiMark accepting such modifications. OptiMark
                  will provide the services pursuant to the Monthly Work Plan,
                  as may be modified. If Nasdaq does not communicate any
                  modifications within such four (4) day period, then the
                  Monthly Work Plan shall be deemed acceptable to Nasdaq, such
                  acceptance shall be subject to Nasdaq confirming to OptiMark
                  that it received the Monthly Work Plan. OptiMark shall then
                  provide the New Services to Nasdaq in accordance with the
                  Monthly Work Plan, as modified.

         (b)      Within five (5) days prior to the beginning of each month,
                  OptiMark shall also provide Nasdaq with an invoice for the
                  upcoming month (the "Invoice") in the amount of the Monthly
                  Payment (as defined below), as such amount may be adjusted in
                  accordance with the provisions set forth in Section 2(d)
                  hereof. For purposes of clarification, each Invoice should
                  reflect the amount set forth in the Nasdaq approved Monthly
                  Work Plan with a deduction for any Carryover Value from the
                  previous month.

         (c)      Within five (5) days following the end of each month, OptiMark
                  shall provide Nasdaq with a report (the "Monthly Report") that
                  sets forth the following information with respect to each
                  OptiMark employee or subcontractor who performed work in
                  support of any of the New Services provided to Nasdaq during
                  the month: (i) name; (ii) title; (iii) rate (as listed in
                  Attachment 2); (iii) actual number of hours worked during the
                  month; and (iv) the New Services performed during the month.

         (d)      Subject to Nasdaq's approval of the Monthly Work Plan and its
                  receipt of the Invoice, both for the upcoming month, and the
                  Monthly Report for the prior month, Nasdaq shall pay OptiMark
                  a fee as reflected in the Invoice for the New Services (the
                  "Monthly Payment") provided through December 31, 2001;
                  provided, however, that if the value of the New Services
                  provided to Nasdaq in any given month (such value to be
                  determined on a time and materials basis pursuant to the rates
                  listed in Attachment 2) is less than the amount of the Monthly
                  Payment remitted to OptiMark at the beginning of such month
                  (the amount by which the Monthly Payment exceeds the value of
                  the New Services shall be referred to herein as the "Carryover
                  Value"), then OptiMark shall reflect the amount of such
                  Carryover Value on the Invoice for the next succeeding month
                  and Nasdaq shall deduct the amount of the Carryover Value from
                  the Monthly Payment due to OptiMark for the next succeeding
                  month. For purposes of clarification, if Nasdaq modifies the
                  Monthly Work Plan (as permitted pursuant to Section 2(a)) such
                  that the value of the New Services as set forth in the
                  modified Monthly Work Plan is different than the value set
                  forth in the Monthly Work Plan originally delivered by
                  OptiMark, then the modified value shall be used to calculate
                  the Carryover Value. OptiMark shall reimburse Nasdaq for any
                  remaining
<PAGE>   3
                  Carryover Value that exists as of December 31, 2001. It is
                  further agreed by the parties that if, at any time, the
                  cumulative value of the Carryover Values exceeds $700,000,
                  then Nasdaq shall have the right to terminate the Agreement
                  pursuant to Section 9 hereof and OptiMark shall reimburse
                  Nasdaq for any remaining Carryover Value that exists as of the
                  date of termination. The Carryover Value shall not include
                  deficiencies in time or work that are caused by Nasdaq's
                  failure to provide information, software, and/or support
                  associated with the Monthly Work Plan in a timely manner.
                  OptiMark's decision to not perform work in view of the
                  foregoing sentence shall not be made without consultation with
                  Nasdaq.

         (e)      Nasdaq will inspect an OptiMark deliverable and/or service
                  under the Task Order to determine whether, in the reasonable
                  opinion of Nasdaq, the deliverable and/or service is
                  reasonably acceptable. Nasdaq will make this determination
                  based on whether the deliverable and/or service substantially
                  meets (a) the applicable specifications provided to OptiMark,
                  if any; or (b) the work described in the Monthly Work Plan (as
                  may be modified by Nasdaq).

                           (i) If the deliverable and/or service is not
                  accepted, then Nasdaq promptly will advise OptiMark in writing
                  as to which aspect of the deliverable and/or service needs
                  correcting. OptiMark will seek to remedy such aspect and
                  deliver a corrected deliverable and/or service to Nasdaq on a
                  date to be agreed to by Nasdaq and OptiMark.

                           (ii) Following receipt of the corrected deliverable
                  and/or service, Nasdaq will inspect the deliverable and/or
                  service again. If Nasdaq does not accept the corrected
                  deliverable and/or service, then OptiMark will issue a credit
                  on its next Invoice to Nasdaq for the amounts paid for the
                  deliverable and/or service. If Nasdaq accepts the corrected
                  deliverable and/or service, then Nasdaq will pay OptiMark for
                  the original work. Nasdaq will also pay OptiMark for remedial
                  work performed on the deliverable to correct normal and
                  reasonable development errors; provided, however, that the
                  amount to be paid by Nasdaq for such remedial work shall be
                  included as part of OptiMark's next Invoice and will be part
                  of, rather than in addition to, the $700,000 per month Monthly
                  Payment which the parties anticipate that Nasdaq will pay to
                  OptiMark for the provision of New Services. As for remedial
                  work performed on the deliverable to correct other errors,
                  OptiMark and Nasdaq will mutually agree whether OptiMark
                  should be paid for such remedial work. If they cannot so
                  agree, either party may seek alternative dispute resolution
                  pursuant to Section 25 of the Agreement to make this
                  determination. All payments by Nasdaq under this sub-section
                  will be made with its next Monthly Payment.

         (f)      Subject to provisions set forth in Section 2(d) and in this
                  Section 2(f), Nasdaq will make payment via wire transfer
                  within fifteen (15) calendar days after its receipt of the
                  Invoice. If Nasdaq reasonably disputes any item or amount set
                  forth on the Invoice (including, without limitation, the
                  amount of the Carryover Value), Nasdaq will pay all amounts
                  not in dispute; provided, however, that disputed items
<PAGE>   4
                  and/or amounts covered in Section 2(e) will be paid as set
                  forth in the current Invoice, subject to OptiMark and Nasdaq
                  adjusting for amounts in dispute in a later Invoice as
                  provided in Section 2(e). OptiMark will maintain accurate and
                  complete records as to time spent in its performance of the
                  New Services and will allow Nasdaq to examine its records from
                  time to time upon written request, with reasonable notice and
                  during normal business hours, in order that Nasdaq may
                  ascertain the correctness of invoices submitted by OptiMark.
                  Late payments shall bear daily interest at a rate of 1.5% per
                  month.

         (g)      OptiMark shall provide Nasdaq with a twenty (20) percent
                  monthly discount for New Services performed over $840,000 in a
                  given month.

         3.   Term and Termination. The term of the Agreement shall continue in
              full effect until December 31, 2001 unless terminated in
              accordance with Section 19 of the Agreement; provided, however,
              that if Nasdaq terminates the Agreement, except for a termination
              pursuant to Section 9 hereof, prior to December 31, 2001, it shall
              remain obligated to make Monthly Payments of $700,000 to OptiMark
              through December 31, 2001.

         4.   Nasdaq Investments. In consideration of the promises set forth
              herein, OptiMark agrees that all Nasdaq warrants (the "Warrants")
              set forth in Section 2(b)-(f) of the 1998 Warrant Agreement and as
              further described in Section 18.1 of the Agreement, shall fully
              vest as of December 31, 2001 without regard to the Critical
              Milestones listed in the Agreement; provided, however, that
              OptiMark has earned minimum cumulative Monthly Payments under the
              Agreement of at least $7,700,000 for New Services performed
              through December 31, 2001 (except that if OptiMark has failed to
              earn cumulative Monthly Payments of at least $7,700,000 due to
              OptiMark's material breach hereof for which Nasdaq has terminated
              the Agreement pursuant to Section 9 hereof, then, the Warrants
              shall, nevertheless, fully vest as of December 31, 2001). The
              exercise date shall remain as stated in Section 18.1 of the
              Agreement. In addition to the obligations set forth in Section
              26.10 of the Agreement, this provision shall also survive any
              termination or cancellation.

         5.   Exclusivity. The first sentence of Section 13.1 of the Agreement
              is deleted in its entirety and replaced with the following:
              OptiMark (including any Affiliates) shall not directly or
              indirectly (including permitting a licensee or owner of any
              OptiMark intellectual property the right to) create or market
              systems or services anywhere in the world for any customer in any
              Financial Instrument, without at least fifteen (15) days prior
              Notice to Nasdaq and subject to Nasdaq's right to consent in each
              instance, such consent shall not be unreasonably withheld or
              delayed.

         6.   Attachment 6 is amended by adding the following at the end of
              thereof:

              "Swaps, equity indices, index options, Eurodollar futures and
              spread market, Eurodollar options, government bonds, corporate
              bonds, interest rate swaps and FRA markets, B2B products, mortgage
              backed securities, stock loan, and options exchange."
<PAGE>   5
         7.   A new Section 11.7 is added:

              "EXCEPT AS EXPRESSLY SET FORTH HEREIN, OPTIMARK AND ITS AFFILIATES
              DO NOT MAKE ANY OTHER REPRESENTATIONS OR WARRANTIES WITH RESPECT
              TO THE SOFTWARE, OTHER TECHNOLOGY, OR SERVICES PROVIDED HEREUNDER.
              OPTIMARK AND ITS AFFILIATES EXPRESSLY DISCLAIM ALL OTHER
              REPRESENTATIONS AND WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ANY
              IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A SPECIFIC
              PURPOSE."

         8.   The following is inserted after "Consequential Damages." as the
              first sentence of Section 26.8:

              "THE ENTIRE LIABILITY OF OPTIMARK AND ITS AFFILIATES TO NASDAQ OR
              ANY THIRD PARTY ARISING OUT OF OR IN CONNECTION WITH THIS
              AGREEMENT, OR USE OF THE SOFTWARE OR ANY OTHER TECHNOLOGY OR
              SERVICES PROVIDED BY OPTIMARK UNDER THIS AGREEMENT, HOWEVER CAUSED
              AND ON ANY THEORY OF LIABILITY, INCLUDING CONTRACT, STRICT
              LIABILITY, NEGLIGENCE OR OTHER TORT, SHALL BE LIMITED TO * . This
              Section 26.8, as amended, is effective as of October 2, 2000."

         9.   Section 19.2 is deleted in its entirety and replaced with the
              following:

              "In the event of a material breach by OptiMark, or if the
              cumulative value of the Carryover Values exceeds $700,000 as
              determined pursuant to Section 2(d) hereof, then Nasdaq shall have
              the right to terminate the Agreement with 10 days Notice (with a
              right to cure within such period, if the breach is curable)."

Except as provided herein, the Agreement will continue in full force and effect
until terminated in accordance with its terms. Nasdaq understands that this
amendment to the Agreement shall not binding on OptiMark until the approval of
its board of directors has been obtained. Please acknowledge your agreement by
signing below.

Bob, we, at Nasdaq, look forward to our renewed working relationship provided by
this newly-defined staff integration plan.

                                         Regards,

                                         /s/ Steven J. Randich

                                         Steven J. Randich

Agreed and Accepted as of this 26th day of April, 2001:

OPTIMARK HOLDINGS, INC.

By:  /s/ Robert J Warshaw
     -------------------------
Name: Robert J Warshaw
Title: CEO

Attachment

* This confidential portion has been omitted and filed separately with the
Commission.
<PAGE>   6
                          THE NASDAQ STOCK MARKET, INC.
                     AGREEMENT FOR PROFESSIONAL SERVICES NO.
                          TASK ORDER NO. 00001-2001-03

<TABLE>
<CAPTION>
SERVICES PERFORMED FOR                      SERVICES PERFORMED BY
<S>                                         <C>
THE NASDAQ STOCK MARKET, INC.               OPTIMARK, INC.
SYSTEMS ENGINEERING                         10 EXCHANGE PLACE CENTER
80 MERRITT BLVD.                            JERSEY CITY, NEW JERSEY 07302
TRUMBULL, CT 06611                          (201) 536 7121
</TABLE>

                                            PERFORMANCE OF
                                            SERVICES RESTRICTED TO:
                                            SYSTEM ENGINEERING

SCOPE OF WORK - MPA APPLICATION DEVELOPMENT - SYSTEM ENGINEERING - TEST SUPPORT
SERVICES FOR SUPERMONTAGE

The scope of work includes, but is not limited to, provision of the following
services:

*

Based upon the previously defined services, the currently identified tasks with
estimates include:

*

TASK ORDER PROJECT MANAGER

Dan Moore
203-502-6439
dan.moore@nasd.com

* This confidential portion has been omitted and filed separately with the
Commission.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00025-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00025-of-00352.parquet"}]]